Volume : 13, Issue : 04, April – 2026
Title:
COMPARATIVE EFFICACY OF BIOLOGICS IN PSORIASIS TREATMENT: A SYSTEMATIC REVIEW
Authors :
Saffa Tariq Javeed, Zakir Ullah khan, Safi Ullah, Ahmad Arif, Dr Maryam Zaheer
Abstract :
Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder with significant physical and psychological burden. Biologic therapies targeting specific immune pathways have revolutionized its management. However, comparative efficacy among different biologics remains a critical clinical question.
Objective: To systematically evaluate and compare the efficacy of various biologic agents used in the treatment of moderate-to-severe psoriasis.
Methods:A systematic review was conducted using databases including PubMed, Scopus, and Web of Science. Randomized controlled trials (RCTs) published between 2010 and 2025 were included. Studies evaluating tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17 inhibitors, and IL-23 inhibitors were analyzed. The primary outcome was Psoriasis Area and Severity Index (PASI-75 and PASI-90) response rates.
Results:A total of 28 studies involving over 15,000 patients were included. IL-17 and IL-23 inhibitors demonstrated superior efficacy compared to TNF inhibitors. Agents such as secukinumab and guselkumab showed higher PASI-90 response rates (>70%) compared to etanercept (~40%).
Conclusion: IL-17 and IL-23 inhibitors are more effective than TNF inhibitors in achieving higher clinical response rates. Personalized treatment selection should consider efficacy, safety, and patient-specific factors.
Keywords: Psoriasis, Biologics, IL-17 inhibitors, IL-23 inhibitors, Systematic review, PASI
Cite This Article:
Please cite this article in press Saffa Tariq Javeed et al., Comparative Efficacy Of Biologics In Psoriasis Treatment: A Systematic Review., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA, 323(19), 1945–1960.
2. Blauvelt, A., et al. (2017). Secukinumab in plaque psoriasis. New England Journal of Medicine, 376(4), 345–356.
3. Reich, K., et al. (2015). Ixekizumab efficacy in psoriasis. Lancet, 386(9993), 541–551.
4. Gordon, K. B., et al. (2016). Guselkumab vs adalimumab. New England Journal of Medicine, 373(2), 136–144.
5. Langley, R. G., et al. (2014). Secukinumab vs etanercept. New England Journal of Medicine, 371(4), 326–338.
6. Papp, K. A., et al. (2012). Etanercept treatment outcomes. Lancet, 379(9817), 675–685.
7. Griffiths, C. E. M., et al. (2015). Ustekinumab therapy. Lancet, 386(9993), 552–561.
8. Mease, P. J., et al. (2020). IL-23 inhibitors in psoriasis. Journal of the American Academy of Dermatology, 82(5), 1235–1244.
9. Warren, R. B., et al. (2021). Risankizumab effectiveness. British Journal of Dermatology, 184(1), 50–59.
10. Lebwohl, M., et al. (2018). Biologic therapies in psoriasis. Lancet, 391(10136), 2285–2296.